Surgalign Holdings, Inc.

Surgalign Holdings, Inc. is a medical technology company, which engages in designing, developing, and manufacturing biologic metal and synthetic implants. Its products portfolio include cervical fixation, The Streamline (TL) fixation, motion preservation, orthobiologics, cervical inter-body fusion, TL IBF, and SI joint fusion. It offers coflex interlaminar stabilization device, SImmetry sacroiliac joint fusion system, and Fortilink IBF system with TETRAfuse?3D technology. The company was founded on February 12, 1998 and is headquartered in Deerfield, IL.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RTI Surgical - OEM Business designs, develops, manufactures and distributes biologic, metal and synthetic implants for a global customer base. Its implants are used in a variety of surgical procedures including orthopaedic, spine, sports medicine, general surgery and trauma.

DEERFIELD, Ill., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its third quarter ended September 30, 2022 after the close of trading on November 2, 2022.

Surgalign Schedules Third Quarter 2022 Earnings Release for November 2, 2022

DEERFIELD, Ill., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (NASDAQ: SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced that it has granted restricted stock unit awards to two (2) employees, none of whom was an executive officer, as an inducement for them to accept employment with Surgalign, and representing the right to receive, in the aggregate, up to 10,081 shares of Surgalign common stock. The award was granted on October 03, 2022 and it was made under the Surgalign Holdings, Inc. 2021 Inducement Plan. One-third of the restricted stock units vest on the first anniversary of the date of grant, and one-eighth of the remaining restricted stock units vest on each subsequent quarterly anniversary of the date of grant, such that the award will be fully vested on the third anniversary of the date of grant, subject to continued employment through the applicable vesting date.

Surgalign Holdings, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Broadens Fortilink interbody product line to now include both titanium and 3D-printed polymer options Broadens Fortilink interbody product line to now include both titanium and 3D-printed polymer options

Surgalign Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures

Company to showcase its HOLO Portal™ surgical guidance system for the first time at an industry event, with live, hands-on demonstrations from surgeons and medical professionals Company to showcase its HOLO Portal™ surgical guidance system for the first time at an industry event, with live, hands-on demonstrations from surgeons and medical professionals

Surgalign to Exhibit at the Society for Minimally Invasive Spine Surgery (“SMISS”) Annual Forum and the North American Spine Society (“NASS”) 2022 Annual Meeting

DEERFIELD, Ill., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced FDA 510(k) clearance of the CorteraTM Spinal Fixation System. This new flagship product from Surgalign is a key piece to the foundational portfolio designed to drive the Company's future growth over the next 10 years and to enable market share gains in the estimated $2.2B US posterior fixation market.

Surgalign Announces FDA 510(k) Clearance of the Cortera™ Spinal Fixation System – The Company's New Flagship Posterior Fixation Platform

Parties enter into new sole-source supply relationship, extended for two years Parties enter into new sole-source supply relationship, extended for two years

Surgalign Announces Global Settlement Agreement with Resolve Surgical Technologies and RTI Surgical, Inc.

Surgalign Holdings, Inc. (NASDAQ:SRGA ) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants David Lyle - Chief Financial Officer Terry Rich - President and Chief Executive Officer Chris Thunander - Chief Accounting Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Operator Good day ladies and gentlemen and welcome to the Surgalign Holdings, Incorporated Second Quarter 2022 Results Conference Call. All lines have been placed in a listen only mode and the floor will be open for your questions and comments following the presentation.

Surgalign Holdings, Inc. (SRGA) CEO Terry Rich on Q2 2022 Results - Earnings Call Transcript

DEERFIELD, Ill., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced financial results for its 2022 second quarter ended June 30, 2022.

Surgalign Holdings, Inc. Announces Second Quarter 2022 Results and Reiterates Full Year 2022 Revenue Guidance Range

DEERFIELD, Ill., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the appointment of Paolo Amoruso as its new General Counsel and Corporate Secretary, effective August 1, 2022. He previously served as Interim General Counsel of Surgalign, having joined the Company in April 2022.

Surgalign Names Paolo Amoruso Chief Legal Officer and Corporate Secretary

DEERFIELD, Ill., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) reached a settlement with the U.S. Securities and Exchange Commission (“SEC”) on August 3, 2022, concluding and resolving in its entirety the previously disclosed SEC investigation relating to activities that occurred between 2015 and 2019 by RTI Surgical Holdings, Inc., and RTI Surgical, Inc. and the prior management. As reflected in the SEC's Order, those activities included pulling sales forward from future quarters to address projected quarterly revenue shortfalls.

Surgalign Reaches Settlement with the Securities and Exchange Commission on Matters Related to Prior Management Between 2015-2019

DEERFIELD, Ill., July 20, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the commercial relaunch of its CervAlign® anterior cervical plate (ACP) system. This next generation plate design comes with an enhanced locking system design and enhances the Company's position in one of the largest procedural categories in spine—the anterior cervical discectomy and fusion (ACDF) market.

Surgalign Announces the Commercial Relaunch of its Next Generation CervAlign Anterior Cervical Plate System Optimized for Discectomy and Fusion Procedures

Program to aid in patient access to Surgalign's Coflex® Interlaminar Stabilization® and SImmetry® SI Joint Fusion Systems

Surgalign Announces Partnership with PRIA Healthcare to Improve Patient Healthcare Coverage

Surgalign Holdings Inc (NASDAQ: SRGA) shares are trading lower by 19.73% at $0.15 after the company announced a 1-for-30 reverse stock split. The 1-for-30 reverse stock split will take effect at the opening of trading on the Nasdaq Global Select Market on Tuesday.

Here's Why Surgalign Holdings Shares Are Falling Today

DEERFIELD, Ill., May 16, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced that at its Annual Meeting of Stockholders (“Annual Meeting”) on May 10, 2022, the Board and stockholders of the Company approved a reverse stock split of the Company's issued and outstanding shares of its common stock and authorized the Board to select the ratio of the reverse stock split.

Surgalign Holdings, Inc. Announces 1-for-30 Reverse Stock Split

Surgalign Holdings, Inc. (NASDAQ:SRGA ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants David Lyle – Chief Financial Officer Terry Rich – President and Chief Executive Officer Chris Thunander – Chief Accounting Officer Conference Call Participants Brooks O'Neil – Lake Street Capital Matt Hewitt – Craig-Hallum Operator Greetings, and welcome to the Surgalign Holdings, Incorporated First Quarter 2022 Results Conference Call. At this time, all participants are in a listen-only mode.

Surgalign Holdings' (SRGA) CEO Terry Rich on Q1 2022 Results - Earnings Call Transcript

DEERFIELD, Ill., May 10, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced financial results for its 2022 first quarter ended March 31, 2022.

Surgalign Holdings, Inc. Announces First Quarter 2022 Results and Raises Full Year 2022 Revenue Guidance Range

DEERFIELD, Ill., May 06, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (NASDAQ: SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced that it has granted restricted stock unit awards to one (1) employee, who was not an executive officer as an inducement for him to accept employment with Surgalign, and representing the right to receive, in the aggregate, up to 37,500 shares of Surgalign common stock. The award was granted on May 2, 2022 and it was made under the Surgalign Holdings, Inc. 2021 Inducement Plan. One-third of the restricted stock units vest on the first anniversary of the date of grant, and one-eighth of the remaining restricted stock units vest on each subsequent quarterly anniversary of the date of grant, such that the award will be fully vested on the third anniversary of the date of grant, subject to continued employment through the applicable vesting date.

Surgalign Holdings, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

DEERFIELD, Ill., April 26, 2022 (GLOBE NEWSWIRE) -- Surgalign Spine Technologies, (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care through the evolution of digital surgery, today announced it plans to release financial results from the first quarter 2022 after the close of trading on May 10th, 2022.

Surgalign Holdings, Inc. Schedules First Quarter 2022 Earnings Release for May 10, 2022

Study published in the IJSS shows Surgalign product to be a reliable solution for SIJ dysfunction Study published in the IJSS shows Surgalign product to be a reliable solution for SIJ dysfunction

New EVoluSIon Study Data Demonstrates Strong Support for the SImmetry® Sacroiliac Joint Fusion System

Surgalign Holdings, Inc. (SRGA) CEO Terry Rich on Q4 2021 Results - Earnings Call Transcript

DEERFIELD, Ill., March 15, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today reported operating results for the fourth quarter and full year 2021.

Surgalign Holdings, Inc. Announces Fourth Quarter and Full Year 2021 Results

DEERFIELD, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced it plans to release financial results from the fourth quarter and full year 2021 after the close of trading on March 15, 2022.

Surgalign Holdings, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release for March 15, 2022

DEERFIELD, Ill., March 07, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (NASDAQ: SRGA) (“Surgalign”), a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the appointment of David Lyle, as Chief Financial Officer, effective immediately.

Surgalign Announces Appointment of David Lyle as Chief Financial Officer

Surgalign Holdings Inc (NASDAQ: SRGA) has priced its previously announced underwritten public offering of 43.47 million and warrants to purchase up to 32.6 million shares at a combined price of $0.46 per share.  The gross proceeds are expected to be approximately $20 million.

Surgalign Shares Tank After $20 Equity Capital Raise

DEERFIELD, Ill., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (NASDAQ: SRGA) (“Surgalign”), a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the pricing of its previously announced underwritten public offering of 43,478,264 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase up to an aggregate of 32,608,698 shares of common stock at a combined effective public offering price of $0.46 per share of common stock (or pre-funded warrant) and accompanying 0.75 of a warrant. Each whole warrant is exercisable immediately at an exercise price of $0.60 per share and will expire five years following the date of issuance. All of the securities being sold in the offering are being offered by Surgalign. The offering is expected to close on or about February 15, 2022, subject to satisfaction of customary closing conditions.

News for Surgalign Holdings, Inc. Stock (SRGA)